Searchable abstracts of presentations at key conferences in endocrinology

ea0067gp19 | Poster Presentations | EYES2019

The trap of endometriosis treatment in the diagnosis of Cushing’s syndrome: Paradoxical response to Dexamethasone or not?

Vasilescu Sorana L , Oros Sabina E , Dumitraşcu Anda

Background: Cushing’s syndrome is the most common cause of endogenous hypercortisolism that results from the excessive exposure to glucocorticoids. Even though this syndrome is represented by a constellation of clinical signs and symptoms, the most common next features are the truncal obesity and the moon facies, making it hard not to be recognized. It is more common in women (F/M=5-8:1) with an avarage age of 20–40 years.Case Presentation: A 3...

ea0070aep773 | Pituitary and Neuroendocrinology | ECE2020

A rare outcome after surgical removal of insulinoma- case presentation

Ghenoiu Sandra , Verdes Andreea , Dumitrașcu Anda , Capatina Cristina , Poiana Catalina

Introduction: Insulinoma is a rare tumor that causes spontaneous fasting hypoglycemia in a supposedly healthy adult. Mostly these tumors are single and benign, few are malignant and a minority is represented by multiple adenomas. The treatment of choice is surgical removal of the insulinoma, which cures the condition in the majority of cases. However, after performing the surgery, less than 10% of patients either develop diabetes mellitus or continue to have persistent hypogly...

ea0073aep482 | Pituitary and Neuroendocrinology | ECE2021

Factors that contribute to dopamine agonist resistance of prolactinomas

Berdeli Maria , Trifanescu Raluca , Caragheorgheopol Andra , Anda Dumitraşcu , Poiana Catalina

IntroductionProlactinomas are the most common hormone-secreting pituitary tumours encountered in the clinic. They are usually treated with dopamine agonists (DA): bromocriptine (BRC) and cabergoline (CAB), which are highly effective in the majority of cases. DA resistance is the failure to achieve normal levels of prolactin and, or reduction of the adenoma with at least 50%.Aimto assess the prevalence of the ...

ea0073aep536 | Pituitary and Neuroendocrinology | ECE2021

Pituitary apoplexy- a single-center, retrospective study of clinical outcomes

Ghenoiu Sandra , Gheorghe Diana Maria , Ciubotaru Gheorghe Vasile , Anda Dumitraşcu , Capatina Cristina , Poiana Catalina

IntroductionPituitary apoplexy is a rare entity characterized by abrupt hemorrhage and/or ischaemia of the constituents of sella turcica. It usually occurs in a previously unsuspected pituitary tumor. It may have an acute or subclinical presentation and it may represent a neuroendocrinological emergency.AimThis study aims to analyze predisposing or precipitating factors, clinical status, imaging and hormonal ...

ea0081p688 | Pituitary and Neuroendocrinology | ECE2022

Implications of the 2017 WHO classification in the characterization of GH-secreting pituitary tumors

Burcea Iulia Florentina , Nicoleta Nastase Valeria , Raluca Ceausu Amalia , Dumitraşcu Anda , Maria Cimpean Anca , Raica Marius , Poiana Catalina

Introduction: Somatotroph pituitary adenomas (PAs) represent 10-15% of all resected PAs, exhibiting immunohistochemical (IHC) positivity for GH (growth hormone) and PIT-1 transcription factor (TF). The histopathological (HP) and IHC variability of each PA influences the phenotype, radiological features, and therapy response.Materials and methods: The study included 33 patients with acromegaly, with men: women ratio of 17:16. The HP-IHC characteristics we...

ea0090ep604 | Endocrine-related Cancer | ECE2023

An unusual etiology of primary hyperparathyroidism in a young woman

Tutoveanu Dan Alexandru , Simona Dragomir Adina , Roxana Boanţă Dana , Simona Dumitraşcu Anda , Ioachim Dumitru

Introduction: Parathyroid carcinoma represents a very rare cause of primary hyperparathyroidism. It can be sporadic (most of cases), but also can occur in association with certain syndromes (multiple endocrine neoplasia, hyperparathyroidism-jaw tumor syndrome or isolated familial hyperparathyroidism).Case report: An 18-year-old woman was referred to the endocrine clinic because of a severe hypercalcemia, detected in the orthopedic surgery department, whe...

ea0070aep663 | Pituitary and Neuroendocrinology | ECE2020

Efficacy of monotherapy versus combined GH receptor antagonist therapy in patients with somatostatin receptor analogues resistant acromegaly

Simona Andreea Găloiu , Margarit Emma , Lavinia Popa Maria , Baciu Ionela , Niculescu Dan , Trifanescu Raluca , Serban Radian , Dumitrașcu Anda , Caragheorgheopol Andra , Poiana Catalina

Background and Aims: GH receptor antagonist (Pegvisomant –PEG) has been shown to obtain IGF1 normalization in 60–90% of patients with acromegaly in clinical trials. The aim of the study is to evaluate real life response and side effects of PEG treatment in monotherapy versus combined with somatostatin analogues and/or cabergoline in patients with somatostatin analogues resistant acromegaly.Methods: We included 40 patients (22F/18 M) cons...

ea0070ep327 | Pituitary and Neuroendocrinology | ECE2020

Conservative management of pituitary apoplexy – a case series

Trifanescu Raluca , Niculescu Dan Alexandru , Cristescu Alexandru , Alexandra Smarandoiu Georgiana , Dobre Ramona , Caragheorgheopol Andra , Hortopan Dan , Dumitrașcu Anda , Poiana Catalina

Introduction: Pituitary apoplexy is a rare complication in 2%-12% of pituitary adenomas, due to sudden hemorrhage or infarction. Patients with signs of meningeal irritation, important visual field defects, ocular paresis, decreased unilateral or bilateral visual acuity or altered consciousness are treated by neurosurgical intervention, while patients without these signs could be managed conservatively.Aim: To present a series of 4 cases with pituitary ap...